Research Article
Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study
Table 1
Baseline features and treatment during follow-up of the overall cohort.
| Baseline features |
| Sex: F/M ratio (%) | 633/113 (84.8%) | Age (years) | | Median (IQR) | 60.9 (52–68.6) | Mean ± SD | 59.5 ± 13 | Disease duration, years from onset | | Median (IQR) | 11.9 (7.37–18) | RF+/−, (%) | 436/304 (58.9%) | ACPA+/−, (%) | 371/349 (52%) | Erosion+/−, (%) | 429/282 (60%) | SDAI baseline | | Median (IQR) | 14 (7.2–22.9) | HAQ-DI baseline | | Median (IQR) | 1 (0.5–1.5) | Smoke+/−, (%) | 325/397 (45%) | Hypertension+/−, (%) | 367/379 (49%) | Diabetes+/−, (%) | 96/650 (13%) | Hypercholesterolemia+/−, (%) | 276/449 (38%) | Obesity+/−, (%) | 112/631 (15%) |
| Treatment during follow-up |
| Anti-TNF, (%) | 393/353 (52.6%) | Mean duration (years) | 5.23 | Non-anti-TNF-bDMARDs, (%) | 209/536 (28%) | Mean duration (years) | 3.68 | MTX+/−, (%) | 649/97 (87%) | Mean duration (years) | 6.16 | Other csDMARDs+/−, (%) Mean duration (years) | Leflunomide 182/564 (24.4%); yrs 4.06 Sulfasalazine 127/617 (17%); yrs 2.8 Hydroxychloroquine 288/458 (38.6%); yrs 4.25 | Low-dose steroids (2.5–5 mg), (%) | 651/95 (87.2%) | Mean duration (years)+ | 6.88 | Cumulative dose of steroids (g) | | Mean ± SD | 1.08 ± 1.07 | Statin+/−, (%) | 149/494 (19.2%) | Mean duration (years) | 5.15 |
|
|
IQR: interquartile range; SD: standard deviation; RF: rheumatoid factor; ACPA: anti-citrullinated cyclic peptide antibodies; SDAI: Simplified Disease Activity Index; HAQ-DI: Health Assessment Questionnaire-Disability Index; TNF: tumor necrosis factor; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARDs: biological disease-modifying antirheumatic drugs; MTX: methotrexate; ASA: acetylsalicylic acid.
|